Versartis, Inc. (NASDAQ:VSAR) shot up 15.8% during trading on Thursday . The company traded as high as $2.40 and last traded at $2.35. 2,811,700 shares traded hands during trading, an increase of 242% from the average session volume of 822,591 shares. The stock had previously closed at $2.03.

A number of brokerages have commented on VSAR. Canaccord Genuity restated a “buy” rating and set a $9.00 price objective (down from $28.00) on shares of Versartis in a research report on Friday, September 22nd. Morgan Stanley reaffirmed an “equal weight” rating and set a $4.00 price target (up from $3.00) on shares of Versartis in a research note on Friday, September 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $14.00 price target (down from $34.00) on shares of Versartis in a research note on Friday, September 22nd. SunTrust Banks downgraded Versartis from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $4.00 in a research note on Friday, September 22nd. Finally, Cowen downgraded Versartis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $45.00 to $3.00 in a research note on Friday, September 22nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. Versartis currently has an average rating of “Hold” and a consensus price target of $7.22.

The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.

Versartis (NASDAQ:VSAR) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.78). During the same quarter in the previous year, the business earned ($0.92) earnings per share. equities analysts anticipate that Versartis, Inc. will post -4.14 earnings per share for the current fiscal year.

In other Versartis news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $3.29, for a total value of $7,007,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Srinivas Akkaraju bought 513,872 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was acquired at an average cost of $2.21 per share, with a total value of $1,135,657.12. Following the completion of the purchase, the director now owns 14,955 shares of the company’s stock, valued at approximately $33,050.55. The disclosure for this purchase can be found here. Over the last three months, insiders sold 2,132,769 shares of company stock valued at $7,014,761. Insiders own 10.90% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. Orbimed Advisors LLC acquired a new position in shares of Versartis during the third quarter worth about $123,000. Bank of America Corp DE boosted its position in shares of Versartis by 46.3% during the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 3,001 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Versartis during the second quarter worth about $218,000. Numeric Investors LLC acquired a new position in shares of Versartis during the second quarter worth about $246,000. Finally, Voya Investment Management LLC boosted its position in shares of Versartis by 26.1% during the second quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 3,094 shares during the period. 49.18% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/07/versartis-vsar-shares-up-15-8.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Receive News & Stock Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related stocks with our FREE daily email newsletter.